ClinVar Miner

Submissions for variant NM_000090.4(COL3A1):c.2312G>A (p.Gly771Asp)

dbSNP: rs1060500193
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV000474051 SCV000541789 likely pathogenic Ehlers-Danlos syndrome, type 4 2016-08-25 criteria provided, single submitter clinical testing In summary, this variant is a novel missense change that affects one of the glycine residues within the triple helix of the COL3A1 protein. For these reasons, it has been classified as Likely Pathogenic. Glycine residues within the triple helix region are important for fibrillar collagens structure and stability (PMID: 7695699, 19344236). In the case of COL3A1 the majority of the missense substitutions at the triple helix domain affect glycine residues (PMID: 24922459, 25758994). This variant is not present in population databases (ExAC no frequency) and has not been reported in the literature in individuals with a COL3A1-related disease. This sequence change replaces glycine with aspartic acid at codon 771 of the COL3A1 protein (p.Gly771Asp). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and aspartic acid.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.